A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study To Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Administered By

Awarded By

Contributors

Start/End

  • January 15, 2019 - January 31, 2024